Is ritexitinib sold in China and how much does it cost?

Ritexitinib, a newly launched drug in the domestic market, has not yet been included in the medical insurance system, which means that patients need to bear all costs when purchasing this drug. Currently, the latest selling price of this drug in China is approximately 3,200 yuan, which may be a considerable financial burden for many patients. However, for those patients seeking a more affordable option, the generic version of Lucius available in Laos may be a viable alternative. This generic drug is officially on the market in Laos, and the price is more affordable. The latest price is around 2,000 yuan.

Ritexitinib is a highly selective inhibitor that mainly acts on tyrosine kinases expressed in the Januskinase3 (JAK 3) and hepatocellular carcinoma (TEC) kinase families. It is precisely because of this highly selective inhibitory effect that it has significant effects in the treatment of certain specific diseases. Especially in June 2023, the U.S. Food and Drug Administration (FDA) officially approved ritixitinib for the treatment of severe alopecia areata in adults and adolescents aged 12 years and older. This approval undoubtedly brings new treatment options to patients, and also marks an important step in the application of ritexitinib in the pharmaceutical field.

Although the domestic price of ritexitinib is relatively high, it is still an option worth considering for those patients who are in urgent need of effective treatment. In addition, the generic version of Lucius on the Lao market is an affordable and effective option for patients seeking alternative treatment options. In the face of disease, diversified treatment options undoubtedly bring more hope and possibilities to patients.